AUSTIN, Texas, July 19, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Anthony G. Quinn, M.B Ch.B, Ph.D. as the Company’s President and Chief Executive Officer, effective immediately. Dr. Quinn has been a member of the Company’s Board of Directors since 2016 and had served as interim CEO since July 2017.
“Aeglea has made great progress over the last 12 months with compelling data from the Company’s lead program pegzilarginase under Anthony’s leadership,” said Armen Shanafelt, Ph.D., Chairman of Aeglea’s Board of Directors. “The Board is looking forward to continue working with him as we progress through the next phase of Aeglea’s evolution. In addition to his technical expertise, Anthony has shown himself to be an extremely talented executive who focuses on patients and on delivering shareholder value. As a Board, we are excited by both the potential of Aeglea’s pipeline and the clinically relevant treatment effects seen with pegzilarginase in patients with Arginase 1 Deficiency.”
“I am honored to have the opportunity to lead Aeglea at this stage in the Company’s development and thrilled to be able to shape the next stage of our journey with the Aeglea team as we advance therapies with the potential to improve the lives of patients with devastating diseases,” said Dr. Quinn. “The Company occupies a unique and exciting area in the biotechnology industry with its focus on discovering novel human enzyme-based therapeutics for patients with rare genetic diseases and cancer. I believe we are now well positioned for future growth with our pipeline programs and our expanded in-house drug-hunting capabilities.”
Prior to joining Aeglea, Dr. Quinn served as executive vice president, head of research and development, and chief medical officer at Synageva Biopharma Corp. until the company’s acquisition by Alexion Pharmaceuticals in 2015. Dr. Quinn previously served as worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. He also was a professor of dermatology at Barts and The London School of Medicine. Dr. Quinn received his Bachelor of Medical Science and his M.B Ch.B from the University of Dundee, and his Ph.D. from the University of Newcastle upon Tyne. Dr. Quinn completed a postdoctoral fellowship at the University of California San Francisco and is a fellow of the Royal College of Physicians London.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, success in our collaborations and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
investors@aegleabio.com
Media Contact:
David Calusdian
Sharon Merrill Associates
AGLE@investorrelations.com